Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives

High-Grade Serous Ovarian Carcinoma (HGSOC) represents the most prevalent and lethal subtype of ovarian cancer, with approximately 225,000 new cases reported globally each year and a five-year survival rate of merely 49.1%. The clinical management of HGSOC encounters substantial challenges, primaril...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruiting Fu, Ruiyue Hu, Wenting Li, Xifang Lv, Hanwei Zhao, Fuxia Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
high-grade serous ovarian carcinoma (HGSOC)
drug resistance mechanisms
molecular markers
personalized treatment
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1556377/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1556377/full

Similar Items